Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The NAD+-II riboswitch is a structured noncoding RNA domain discovered in bacterial mRNAs that serves as a ligand-activated genetic regulatory element. It specifically recognizes and binds nicotinamide adenine dinucleotide (NAD+), nicotinamide mononucleotide (NMN), and nicotinamide riboside (NR). This riboswitch is termed “NAD+-II” (or class II NAD+ riboswitch) to distinguish it from the NAD+-I riboswitch. It features one aptamer domain (unlike the tandem arrangement in NAD+-I)[6]. Structural studies reveal that it contains complex tertiary RNA folds and forms two distinct ligand-binding pockets that can each bind one ligand molecule predominantly via the nicotinamide moiety of NAD+ or its derivatives[1][3][2]. The NAD+-II riboswitch is typically found upstream of pnuC genes, which encode NR transporters crucial for NAD+ biosynthesis in bacteria and is thus implicated in the regulation of NAD+ transporter expression[5]. While this riboswitch is functionally important for bacterial metabolism and gene regulation, it is not classified as a therapeutic target (receptor, enzyme, transporter, etc.), nor is it currently associated with human disease, pharmacological intervention, or biomarker utility in clinical settings[5][3]. Its value resides in regulating cofactor metabolism and as a model for RNA structure and ligand recognition[3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on NAD+-II riboswitch.